EUVIMEDEUVIMED entdecken
VergleichsstudieRandomisierte kontrollierte Studie

Combination treatment of mirabegron and solifenacin versus solifenacin monotherapy in female patients with overactive bladder – A comparative study on effectiveness, safety, symptoms and quality of life and treatment adherence

Rathindra Nath Ray, Anshu Kumar iD, Ruchita Agarwal, G S Kamilya, Taquedis Noori, Monika Shah

Urologia Journal · 2026

DOI: 10.1177/03915603251378596 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Urologia Journal, 2026. Verfasst von Rathindra Nath Ray und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynaecology, Institute of Post Graduate Medical Education and Research, Kolkata, India. Hauptthemen laut MEDLINE: Solifenacin Succinate, Urinary Bladder, Overactive, Acetanilides, Thiazoles. Die Arbeit nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Compared to other overactive bladder (OAB) symptoms, incontinence has a more negative impact on quality of life and is frequently challenging to treat with antimuscarinic monotherapy. This study’s goal was to compare the safety, tolerability, and effectiveness of a combination of solifenacin 5 mg and mirabegron 25 mg or 50 mg versus solifenacin 5 mg in patients with OAB. Material and methods: In a tertiary care hospital, 258 individuals with overactive bladders participated in a randomised controlled open-label research to examine the safety and efficacy of mirabegron as a supplement to solifenacin. Randomisation was used to assign patients to one of three groups: those receiving solifenacin (5 mg) with mirabegron (25 mg), solifenacin (5 mg) plus mirabegron (50 mg) or solifenacin (5 mg) monotherapy. OABSS was used to examine the patients. A change in the OABSS from baseline to end of treatment (EOT) was the main outcome measure. This research also examined the safety and tolerability of combination treatment in comparison to solifenacin monotherapy.

Results

All combinations with solifenacin five substantially improved the OAB symptoms score as compared to solifenacin 5 mg monotherapy. When compared to solifenacin 5 mg, both combination groups significantly decreased the frequency of micturition. Although there were no dose-related differences between the combination and monotherapy groups in terms of TEAEs, blood pressure, pulse rate, PVR volume, or laboratory or ECG parameters, combination medication did result in a slightly higher frequency of constipation.

Conclusions

When compared to solifenacin 5 mg monotherapy, combination therapy with solifenacin/mirabegron markedly improved OABSS, micturition frequency, and urgency. When compared to monotherapy, all combinations were well tolerated and showed no significant extra safety concerns.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Solifenacin SuccinateUrinary Bladder, OveractiveAcetanilidesThiazolesQuality of LifeMuscarinic AntagonistsUrological AgentsHumansFemaleMiddle AgedDrug Therapy, CombinationTreatment OutcomeAgedAdult

Stichwörter der Autor:innen

Incontinencemirabegronoveractive bladder symptoms scorequalitysolifenacin

Substanzen

mirabegronSolifenacin SuccinateAcetanilidesThiazolesMuscarinic AntagonistsUrological Agents

Autor:innen und Institutionen

  • Department of Obstetrics and Gynaecology, Institute of Post Graduate Medical Education and Research, Kolkata, India.
  • Department of Urology, Tata Main Hospital, Jamshedpur, India.
  • Department of Obstetrics and Gynaecology, Jagannath Gupta Institute of Medical Sciencs and Hospital, Kolkata, India.
  • Department of Urology, Institute of Post Graduate Medical Education and Research, Kolkata, India.

ORCID-Profile: Anshu Kumar

Zitieren

APA

Ray, R. N., Kumar, A., Agarwal, R., Kamilya, G. S., Noori, T., & Shah, M. (2026). Combination treatment of mirabegron and solifenacin versus solifenacin monotherapy in female patients with overactive bladder – A comparative study on effectiveness, safety, symptoms and quality of life and treatment adherence. Urologia Journal. https://doi.org/10.1177/03915603251378596

Vancouver

Ray RN, Kumar A, Agarwal R, Kamilya GS, Noori T, Shah M. Combination treatment of mirabegron and solifenacin versus solifenacin monotherapy in female patients with overactive bladder – A comparative study on effectiveness, safety, symptoms and quality of life and treatment adherence. Urologia Journal. 2026. doi:10.1177/03915603251378596

BibTeX
@article{Ray2026,
  author = {Ray, Rathindra Nath and Kumar, Anshu and Agarwal, Ruchita and Kamilya, G S and Noori, Taquedis and Shah, Monika},
  title = {Combination treatment of mirabegron and solifenacin versus solifenacin monotherapy in female patients with overactive bladder – A comparative study on effectiveness, safety, symptoms and quality of life and treatment adherence},
  journal = {Urologia Journal},
  year = {2026},
  doi = {10.1177/03915603251378596}
}
Kostenlos starten →